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Akt, a serine-threonine protein kinase, exists as
three isoforms. The Akt signaling pathway controls
multiple cellular functions in the cardiovascular
system, and the atheroprotective endothelial cell-
dependent role of Akt1 has been recently demon-
strated. The role of Akt3 isoform in cardiovascular
pathophysiology is not known. We explored the
role of Akt3 in atherosclerosis using mice with
a genetic ablation of the Akt3 gene. Using hyperlipi-
demic ApoE/ mice, we demonstrated a macro-
phage-dependent, atheroprotective role for Akt3.
In vitro experiments demonstrated differential sub-
cellular localization of Akt1 and Akt3 in macrophages
and showed that Akt3 specifically inhibits macro-
phage cholesteryl ester accumulation and foam cell
formation, a critical early event in atherogenesis.
Mechanistically, Akt3 suppresses foam cell forma-
tion by reducing lipoprotein uptake and promoting
ACAT-1 degradation via the ubiquitin-proteasome
pathway. These studies demonstrate the nonredun-
dant atheroprotective role for Akt3 exerted via the
previously unknown link between the Akt signaling
pathway and cholesterol metabolism.
INTRODUCTION
Akt, also known as protein kinase B (PKB), plays an important
role in the regulation of numerous cellular processes including
cell growth, glucose metabolism, differentiation, proliferation,
and apoptosis (Manning and Cantley, 2007). Three Akt isoforms,
encoded by three separate genes, are expressed in mammals.
The three isoforms are highly homologous in their amino acid
sequences and display similar substrate specificity. Phenotypic
analysis of the individual Akt isoforms’ deletion in the mouse
showed distinct phenotypes, which could be at least partially
attributed to their relative expression in the affected tissues or
organs. Combined deletions of the Akt isoforms in the mouse
suggest compensatory and complementary roles of three iso-
forms (Manning and Cantley, 2007). However, the three isoformsCmay have distinct functions, even at the cellular level, even
though the mechanisms of specificity are poorly understood.
Despite recent discoveries, a thorough understanding of the
specific roles of Akt family members and the molecular mecha-
nisms that determine Akt isoform functional specificity is still
lacking.
Akt is at the center of a complex signaling network regulating
multiple cellular functions, suggesting a possibility that Akt
signaling pathways may be involved in pathogenesis of athero-
sclerosis. However, studies of the role of Akt in general, and
specifically Akt isoforms in atherogenesis, are very limited.
Recent studies have shown that the genetic ablation of Akt1
promotes coronary atherosclerosis (Fernandez-Hernando
et al., 2007). The effect of Akt1 deficiency was mostly due to
the enhanced expression of proinflammatory genes in the artery
wall. Bone marrow transplantation experiments demonstrated
that macrophages from ApoE/Akt1/ donors did not confer
increased atherogenesis, suggesting that lesion expansion in
the ApoE/Akt1/ mice might be of vascular origin. In agree-
ment with these results, in vitro studies demonstrated that
Akt1/ macrophages tended to accumulate less cholesterol
when exposed to modified lipoproteins. The roles of Akt2 and
Akt3 isoforms, as well as specific involvement of Akt in lipid
metabolism leading to modulation of atherosclerosis, are
unknown.
In the present study, we explored the role of Akt3 in athero-
sclerosis using mice with a genetic ablation of the Akt3 gene.
We demonstrated a specific, macrophage-dependent, antia-
therosclerotic role for Akt3 in hyperlipidemic ApoE/ mice.
Mechanistically, Akt3 exerts its atheroprotective function
by restricting cholesteryl ester (CE) accumulation in macro-
phages via downregulation of lipoprotein uptake and inhibition
of ACAT-1 protein expression. Thus, our study demonstrates
a nonredundant atheroprotective role for Akt3 exerted via a
link between Akt signaling pathway and lipoprotein and choles-
terol metabolism.
RESULTS
Akt3 Deficiency Promotes Atherosclerosis
in Hyperlipidemic ApoE–/– Mice
To study the functional role of Akt3 in atherogenesis in vivo, we
subjected age- and sex-matched ApoE/Akt3/ and ApoE/
mice to aWestern diet for 9weeks. En face analyses of total aortaell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc. 861
Figure 1. Deficiency of Akt3 Promotes
Atherosclerosis in ApoE–/– Mice
(A) Representative images of en face oil red O
staining of aortas of ApoE/Akt3/ and ApoE/
littermates (eight males and four females in each
group), n = 12.
(B) (Left panel) Representative images of cross-
sections of the aortic sinus stained with oil red O.
(Right panel) Quantification of atheroma area. Six
slides form different layers were taken for analysis
from at least three hearts for each group.
(C) (Left panel) CD68-positive macrophages
(brown) in lesions ofApoE/Akt3/ and ApoE/
mice. (Right panel) Quantification of CD68-posi-
tive areas.
(D) Fasting triglycerides levels of ApoE/Akt3/
and ApoE/ mice after 9 weeks on a Western
diet.
(E–G) Body weight, fasting cholesterol levels,
and lipoprotein profiles from ApoE/ and
ApoE/Akt3/ mice on a normal chow diet or
a Western diet. Data represent means ±SEM.
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lesion area in ApoE/Akt3/ mice (Figure 1A). Lesion areas in
cross-sections of the aortic sinus were also increased 2.2-fold
in ApoE/Akt3/ mice (Figure 1B). The areas infiltrated by
CD68-positive macrophages in lesions were increased 3-fold in
ApoE/Akt3/ mice (Figure 1C). The body weights, plasma
cholesterol levels, plasma triglycerides (TGs), and lipoprotein
profiles were similar between both genotypes fed a Western
diet (Figures 1D–1G). Interestingly, plasma TGs were higher in
ApoE/Akt3/ mice fed a chow diet (Figure S1). Thus, the
genetic loss of Akt3 increases aortic atherogenesis without
changes in plasma cholesterol and lipoprotein profile. A similar
result has been previously published for Akt1/ mice (Fernan-
dez-Hernando et al., 2007), indicating that Akt3 and Akt1 have
nonredundant atheroprotective roles.
Akt3 Expression in Bone Marrow Cells
Is Atheroprotective
To determine whether Akt3 deficiency in bone marrow con-
tributes to atherogenesis, we created ApoE/ chimeric mice
with either ApoE/Akt3/ bone marrow or ApoE/Akt3+/+
bone marrow cells. After 10 weeks on aWestern diet, the area of
atherosclerotic lesions in the aorta was significantly increased in
the ApoE/Akt3/ chimeras (41% increase, Figure 2A), while
body weight, plasma cholesterol, and TGs were undistinguish-862 Cell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc.able in two groups (Figures 2B–2D).
Enhanced lesion areas in the aortic sinus
were also observed in this group (Fig-
ure 2E). The aortic lesions in both groups
consisted mainly of CD68-positive
macrophage foam cells (Figure 2F).
These findings strongly suggest that the
Akt3 expression in macrophages is
atheroprotective. Moreover, a similar
extent of increase in atherosclerosis in
bone marrow chimeras and in whole-
body Akt3 knockouts suggests that lossof Akt3 expression in bone marrow (presumably in macro-
phages) drives an increase in atherosclerosis development in
Akt3 deficiency. Thus, the mechanism of atheroprotective func-
tion of Akt3 is different from that of Akt1.
Akt3 Deficiency Does Not Affect Macrophage Survival
Macrophage apoptosis is an important event in atheroscle-
rosis plaque development (Tabas, 2010). We compared
apoptosis of macrophages in atherosclerotic lesions of
ApoE/ and ApoE/Akt3/ mice. There was no increase
in the percentage of TUNEL-positive CD68-positive macro-
phages (Figure 2G). We also tested in vitro whether Akt3/
thioglycollate-elicited murine peritoneal macrophages (MPMs)
are prone to apoptosis by culturing MPMs in the presence
of acLDL and ACAT inhibitor FR-179254. This condition
induces accumulation of unesterified cholesterol and, con-
sequently, apoptosis in MPMs. While FR-179254 induced
significant increase in apoptosis and a reduction in viability of
MPMs, we saw no statistically significant difference between
wild-type (WT) and Akt3/ MPM, neither in the absence nor
in the presence of FR-179254 (Figures 2H and 2I). These
data indicate that macrophage Akt3 deficiency plays no sig-
nificant role in apoptosis of macrophages, and that proathero-
sclerotic phenotype of Akt3/ macrophages is apoptosis
independent.
Figure 2. Atherosclerotic Lesion Develop-
ment Is Increased in ApoE–/– Chimeras
with ApoE–/–Akt3–/– Bone Marrow
(A) Lesion analyses of aortas from ApoE/
chimeras with ApoE/Akt3/ or ApoE/ bone
marrow, n = 10.
(B) Body weight of ApoE/ chimeras before and
after 10 weeks on a Western diet.
(C and D) Fasting cholesterol and triglycerides
levels of ApoE/ chimeras after 10 weeks on
a Western diet, n = 7.
(E) Representative examples of cross-sections
from the aortic sinus stained with oil red O and
quantification of atheroma area, n = 7.
(F) CD68-positive macrophages (brown) in lesions
of ApoE/Akt3/ and ApoE/ mice. Scale bar,
100 mm; n = 7.
(G) Apoptotic cells and macrophages in lesions of
ApoE/ and ApoE/Akt3/ mice after 9 weeks
of aWestern diet as detected by TUNEL and CD68
staining, respectively. Scale bar, 25 mm; n = 7.
(H and I)Wild-type (WT) andAkt3/macrophages
were treated with acLDL (100 mg/ml) in the pres-
ence or absence of ACAT inhibitor FR-179254,
and (H) apoptosis was detected 48 hr after treat-
ment using Annexin V-FITC or propidium iodide
(PI) staining. Right panel shows quantification of
the data for PI staining. Scale bar, 50 mm; n = 8. (I)
Cell viability was determined by trypan blue
exclusion 24 hr after treatment. n = 8. Data
represent means ±SEM.
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Accumulation and Foam Cell Formation In Vitro
Accumulation of cholesterol and CEs in macrophages and
subsequent foam cell formation is a critical early step in athero-
genesis. We tested whether the deletion of Akt3 affects macro-
phage cholesterol accumulation and foam cell formation
in vitro. The expression of Akt3 in WT MPM and the absence of
Akt3 protein in MPMs of Akt3/ mice were confirmed using
an Akt3-specific antibody (see Figure S2A online). Western blot
analysis of Akt3/ MPMs using pan-Akt antibody revealed
that total Akt levels decreased in Akt3/ MPMs by 25% (Fig-
ure 3A). Total Akt kinase activity was reduced by 20% in
Akt3/MPMs (Figure 3B).Akt3/ andWTMPMswere cultured
in the presence of either native LDL (negative control), acLDL, or
serum from hyperlipidemic ApoE/ mice known to contain
atherogenic lipoprotein. We also used LDL modified by mild
oxidation by the MPO-H2O2-NO2
 system, or strong oxidation
by Cu2+. The initial cholesterol and CE content of Akt3/
MPMs was indistinguishable from that of WT MPMs (Figure 3C).
However, after 24 hr of exposure to modified LDL, Akt3/
MPMs accumulated significantly more CE than did WT MPMs
(Figures 3C and 3D; data for acLDL and hyperlipidemic serum
are shown). Increase in unesterified cholesterol content was
less pronounced. Neither MPM accumulated a significant
amount of cholesterol upon incubation with native LDL as antic-
ipated (data not shown). Neutral lipid staining with oil red O also
revealed a noticeable increase in foam cell formation in Akt3/
MPMs exposed to either acLDL or serum from hyperlipidemic
ApoE/ mice as compared to WT MPMs (Figure S2B). This
effect was specific for Akt3, since Akt1/ MPMs displayedCreduced foam cell formation as compared to WT MPM (Fig-
ure S2C), in agreement with published data (Fernandez-Her-
nando et al., 2007). We also assessed CE formation by
measuring the incorporation of [14C]oleate into the CE of
MPMs. Taking into account that variations in cholesterol efflux
can contribute to cholesterol accumulation in MPMs, we
exposed Akt3/ and WT MPMs to increasing concentrations
of acLDL in the media containing either no specific cholesterol
acceptors (bovine serum albumin, BSA), only nonlipoprotein
cholesterol acceptors (lipoprotein-deficient serum, LPDS), or
complete spectrum of cholesterol acceptors (fetal bovine serum,
FBS) (Figure 3E). We observed dose-dependent increases in CE
formation in both Akt3/ and WT MPMs; however, the increase
was more pronounced in Akt3/ MPMs in all conditions used.
Thus Akt3 deficiency in MPM is associated with increased accu-
mulation of CE and increased macrophage foam cell formation
in vitro.
Akt3–/– MPMs Display Mild Increase in Uptake
of Modified LDL and No Significant Change
in De Novo Cholesterol Synthesis
To investigate whether the enhanced CE accumulation and foam
cell formation in Akt3/macrophages was due to an increased
uptake of modified forms of LDL, we first assessed the expres-
sion of major scavenger receptors (CD36, SR-AI, and LOX-1) in
Akt3/ and WT MPMs. No significant difference between the
two groups was observed (Figure 4A). Since modified LDL can
modulate the expression of scavenger receptors on macro-
phages (Han and Nicholson, 1998), we compared the expression
of scavenger receptors on MPMs exposed to modified LDL.ell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc. 863
Figure 3. Deficiency of Akt3 in Murine Peritoneal Macrophages Promotes Cholesterol Ester Accumulation
(A) Western blot analyses of total Akt expression (using pan-Akt antibodies) in MPMs of wild-type (WT) and Akt3/ (Akt3 KO) mice. n = 5.
(B) In vitro Akt kinase assay of MPM from WT and Akt3/ mice. n = 5.
(C and D) The content of unesterified cholesterol and CE in WT and Akt3/ MPMs before or after 24 hr incubation in (C) RPMI/10% LPDS medium containing
50 mg/ml acLDL or (D) RPMI containing 15% serum from hyperlipidemic ApoE/ mice. n = 5.
(E) Cholesterol [14C]oleate synthesis in WT and Akt3/MPMs incubated for 24 hr with indicated concentrations of acLDL and 1.5 mCi/ml [14C]oleic acid in RPMI
containing either BSA, LPDS, or FBS. n = 5. Data represent means ±SEM. *p < 0.05.
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observed (Figures 4B and Figure S3A). Furthermore, binding
assay at 4Cusingmodified LDL ligands for scavenger receptors
revealed no significant difference between Akt3/ and WT
MPMs (Figure 4C), demonstrating that Akt3 deficiency does
not induce expression of scavenger receptors. Since alternative
pathways have been described to mediate the uptake of modi-
fied LDL, such as macro- and micropinocytosis, phagocytosis,
and contribution of other receptors, we assessed uptake of
modified LDL at 37C. We observed moderate and uniform
increases in uptake of all forms of modified LDL tested by
Akt3/MPM (Figure 4D). Since scavenger receptor expression
was similar, these increases are probably explained by a small
increase in pinocytosis that we observed in Akt3/ MPM (Fig-
ure 4E). Even though these increases are small, theoretically
they still may contribute to accumulation of cholesterol in
Akt3/ MPM.
Akt signaling pathways were recently implicated in the regula-
tion of cholesterol synthesis. Theoretically, de novo cholesterol
synthesis can contribute to the accumulation of cholesterol in
macrophages. However, we found no significant difference in
cholesterol synthesisbetweenAkt3/andWTMPMinconditions
that stimulate cholesterol synthesis (in the presence of LPDS), nor
in conditions of increased cholesterol uptake and suppressed
cholesterol synthesis (in thepresenceofmodifiedLDL) (Figure4F).
These results suggest that Akt3 isoform is not involved in the
regulation of cholesterol synthesis in macrophages, and, con-
sequently, increased cholesterol synthesis does not contribute
to the observed accumulation of CE in Akt3/macrophages.864 Cell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc.Cholesterol Ester Hydrolysis Is Not Changed
in Akt3–/– MPMs
Since we found only a modest 10%–15% increase in lipoprotein
cholesterol uptake (Figure 4D) and no significant changes in
cholesterol synthesis in Akt3/ macrophages (Figure 4F), the
only way to significantly increase CE content in MPM is via
a reduction of efflux of lipoprotein-derived cholesterol. The
question remains, is this decrease due to a primary effect on
the efflux machinery, or secondary, due to (1) the defect in lyso-
somal hydrolysis of lipoprotein-derived CE, (2) an increased
esterification of cholesterol by ACAT, or (3) a reduced hydrolysis
of ACAT-derived CE by neutral CE hydrolases. To test the
possibility that a defect in the hydrolysis of LDL-derived CE
exists in Akt3/ MPMs, we incubated MPMs with acLDL in
the presence of the ACAT inhibitor FR179254. Inhibition of CE
synthesis by FR179254 in WT and Akt3/ MPMs was associ-
ated with complete suppression of neutral lipid accumulation,
demonstrating that the accumulation of CE in Akt3/ MPMs
is ACAT dependent (Figure S3B). The possibility of changes in
hydrolysis of endogenously formed CE in Akt3/ MPMs was
then investigated. LIPE, or hormone sensitive lipase, and
nCEH1 account for nearly 90% of CE hydrolysis in macro-
phages (Sekiya et al., 2009). The expression of both enzymes
in WT and Akt3/ macrophages was similar (Figure 4G). We
also assessed the rate of CE hydrolysis in CE-laden cultured
MPMs, and found that the rates were almost identical in WT
and Akt3/ macrophages (Figure 4H). Together, these data
indicate that Akt3 deficiency does not suppress CE hydrolysis
in MPM.
Figure 4. Deletion of Akt3 Does Not Significantly Change Macrophage Expression of Main Scavenger Receptors, Main Cholesteryl Ester
Hydrolases, Cholesterol Synthesis, and Hydrolysis of Cholesterol Esters and Results in Mild Increase in Uptake of Modified LDL
(A) Western blot analyses of scavenger receptor (CD36, SR-AI, LOX-1) expression on MPMs of WT and Akt3/ mice. n = 6.
(B) Expression of CD36 and SR-AI on MPM after 18 hr incubation with or without 50 mg/ml of modified LDL. Graph below shows densitometric quantification.
MPMs from CD36/ mice were used as a negative control of CD36 expression. n = 6.
(C) MPMs from WT and Akt3/ mice were incubated for 2 hr on ice with 10 mg/ml of 125I-labeled native or modified LDL, and total bound 125I was quantified.
n = 5.
(D) MPMs from WT and Akt3/mice were incubated for 6 hr 37C with 10 mg/ml of 125I-labeled native or modified LDL, and total uptake of 125I-lipoprotein was
quantified. n = 6.
(E) Uptake of the lucifer yellow fluid-phase dye as a measure of pinocytosis in WT and Akt3/ MPMs. n = 6.
(F) [14C]Cholesterol synthesis determined by the incorporation of [14C] acetyl CoA in [14C]cholesterol in WT and Akt3/ MPMs cultured in RPMI/10% FBS,
RPMI/10% LPDS or RPMI/10% LPDS + 50 mg/ml acLDL (for details, see the Supplemental Information). n = 6.
(G) Western blot analyses of CE hydrolase (nCEH, HSL) expression in MPMs of WT and Akt3/ mice. n = 5.
(H) Hydrolysis of cholesteryl [14C]oleate in WT and Akt3/ MPMs in the presence of ACAT inhibitor (for details, see the Supplemental Information). n = 5.
Data represent means ±SEM. *p < 0.05.
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in Akt3–/– MPMs
Excess free cholesterol in macrophages undergoes esterifica-
tion by acyl-CoA:cholesterol acyltransferase (SOAT or ACAT).
Two isoforms of ACAT (ACAT-1 and ACAT-2) are found in
mammalian cells (Li and Glass, 2002). We assessed both protein
expression and enzyme activity of ACAT-1 and ACAT-2 in
Akt3/ and WT MPM. Akt3 deficiency led to elevated expres-
sion of ACAT-1 protein (35% increase), while no noticeable
change in ACAT-2 protein expression was detected (Figures
5A and 5B). Expression of ACAT-1 inAkt3/MPMswas upregu-
lated upon incubation with acLDL and was 2.5-fold higher
compared to WT MPMs (Figure 5C). In contrast, changes in
ACAT-2 expression in response to incubation with acLDL were
modest (Figure 5D). Akt3 deficiency in MPM was associatedCwith a 1.9-fold increase in ACAT enzymatic activity (Figure 5E).
Cholesterol loading after incubation with acLDL led to further
increases in ACAT activity in both WT and Akt3/ MPMs;
however, ACAT activity was still 2-fold higher in Akt3/ MPM.
While western blot analysis revealed an increased expression
of both ACAT-1 and ACAT-2 after exposure to acLDL, ACAT-2
is considered to play no significant role in the accumulation of
CE in macrophages (Rudel et al., 2001). We performed foam
cell formation and CE synthesis assays in the presence of
a selective ACAT-2 inhibitor, pyripyropene A (PPPA) (Das et al.,
2008), and confirmed that ACAT-1 is the major isoform of
ACAT responsible for cholesterol accumulation in Akt3/
MPMs (Figures S4A–S4C). These data suggest that increased
ACAT-1 expression and activity may play a significant role in
excessive CE accumulation in Akt3/ MPMs.ell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc. 865
Figure 5. Akt3–/– Macrophages Have Increased Expression and Activity of Acyl-CoA:Cholesterol Acyltransferase and Have No Significant
Changes in Cholesterol Efflux
(A) Western blot analyses of ACAT-1 and ACAT-2 expression in WT and Akt3/ MPMs. n = 4.
(B) Immunofluorescence staining of ACAT-1 in WT and Akt3/ MPMs. Scale bar, 100 mm.
(C and D) Immunoprecipitation and subsequent western blot analysis and densitometric quantification of ACAT-1 and ACAT-2 in MPMs of WT or Akt3/ mice
after 18 hr incubation with or without (ctl) 50 mg/ml of acLDL. n = 6.
(E) In vitro ACAT activity in lysates of WT and Akt3/ MPMs after 18 hr -incubation with or without 50 mg/ml of acLDL. n = 6.
(F) Western blot analysis of ABCA-1, ABCG-1, and SR-BI expression in WT and Akt3/ MPM. n = 3.
(G) The content of unesterified and esterified cholesterol in WT and Akt3/MPMs incubated with 50 mg/ml acLDL in the presence of indicated concentrations of
ACAT inhibitor FR179254. n = 5.
(H) MPMs from WT or Akt3/ mice were incubated overnight with 100 mg/ml of acLDL and 3 mCi/ml 3H-cholesterol, washed, and equilibrated, and then
cholesterol efflux was assessed into the media containing either 0.5% BSA, 5% LPDS, 50 mg/ml ApoA-I, or 100 mg/ml HDL in the presence of 80 nM FR179254
over a 24 hr period. n = 6. Data represent means ±SEM. *p < 0.05; **p < 0.01.
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in Cholesterol Efflux
We next tested whether Akt3/MPMs have a primary defect in
cholesterol efflux. Lack of Akt3 expression has no noticeable
effect on the expression of major mediators of cholesterol efflux
ABCA1, ABCG1, or SR-BI on MPMs (Figure 5F). Initial experi-
ments using 3H-cholesterol tracer showed modestly reduced
(5%–15% reduction) cholesterol efflux in Akt3/ MPMs (Fig-
ure S4D). Since increased activity of ACAT-1 in Akt3/ MPMs866 Cell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc.can reduce the pool of 3H-cholesterol available for efflux, we
next repeated cholesterol efflux experiments and performed
direct measurements of cellular cholesterol mass in the
presence of ACAT-1 inhibitor (Figures 5G and 5H). Cholesterol
efflux from WT and Akt3/ MPMs under these conditions
was practically identical (Figure 5H). Inhibition of cholesterol
esterification in MPMs exposed to modified LDL resulted in an
increase in unesterified cholesterolmass, both inWTandAkt3/
macrophages, as expected (Figure 5G). However, in agreement
Figure 6. Inhibition of Akt3, but Not Akt1, by
siRNA Promotes Foam Cell Formation in
MPMs
(A–C) MPMs were transfected with either control
siRNA or Akt1-specific or Akt3-specific siRNAs for
48 hr. Western blot was performed using anti-
Akt1-, Akt3-, or GAPDH-specific antibodies.
(D) Foam cell formation in siRNA-treated MPMs.
MPMs were transfected with siRNA for 72 hr and
further incubated with 50 mg/ml acLDL in RPMI/
0.5% BSA for 18 hr, then fixed and stained with oil
red O. Right panel shows quantification of foam
cells. Scale bar, 25 mm.
(E) MPMs were transfected as in (D) and incubated
with 50 mg/ml of acLDL and 0.3 mCi/ml [14C]oleic
acid for 24 hr, and cholesterol [14C]oleate
synthesis was assessed. n = 5. Data represent
means ±SEM.
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no difference in cholesterol content between WT and Akt3/
macrophages under these conditions. These experiments rule
out a primary defect in cholesterol efflux from Akt3/MPMs as
a mechanism leading to increased CE accumulation in Akt3/
MPMs. They further suggest that a net decrease in cholesterol
efflux of lipoprotein-derived cholesterol is secondary to
enhanced cholesterol esterification mediated by ACAT-1.
Downregulation of Macrophage Akt3 Expression
Augments CE Synthesis and Foam Cell Formation
In Vitro
To test whether suppression of the expression of Akt3 in MPMs
in vitro is sufficient to induce ACAT-1 expression and CE
accumulation, we used the small interfering RNA to inhibit
Akt3 expression in WT MPMs, and then performed foam cell
formation and CE synthesis assays. As additional control, we
used the same approach to suppress the expression of Akt1 in
WT MPMs. Transfection with Akt3 siRNA significantly inhibited
the expression of Akt3 without having an effect on Akt1 expres-
sion (Figures 6A and 6C and Figure S5A). In turn, Akt1 siRNA
specifically inhibited Akt1 expression (Figure 6B and Figure S5A).
Transfection efficiency in these experiments assessed using
FITC-conjugated control siRNA reached 55% (Figure S5B).
There were no significant changes in the subcellular distribution
of Akt1 and Akt3 after treatment with specific siRNAs (Fig-
ure S5A). Inhibition of Akt3 expression resulted in increase in
macrophage foam cell formation and in cholesteryl [14C]oleate
synthesis (Figures 6D and 6E). In contrast, inhibition of Akt1
expression tended to reduce foam cell formation and CE
synthesis in MPMs. These results further support the direct
and specific role of Akt3 in the excessive cholesterol accumu-
lation in MPMs.
Akt1 and Akt3 Have Different Subcellular Distribution
in Macrophages
To find out why Akt1 and Akt3 deficiencies lead to opposite
effects on macrophage CE accumulation, we examined theCsubcellular distribution of Akt1 and Akt3 in macrophages. Immu-
nofluorescent staining showed distinct localizations of Akt1
and Akt3 in WT MPMs. Akt1 was mainly located in the nucleus,
while themajority of Akt3was located in the cytoplasm (Figure 7A
and Figure S6A). The deletion of Akt3 led to no obvious change
in Akt1 distribution in MPMs, suggesting that Akt1 cannot
compensate for the lack of Akt3 expression (Figure 7B). The
localization of Akt1 and Akt3 in human differentiated THP-1
macrophages was similar to that in MPMs (Figure 7C). This
distribution of Akt3 and Akt1 was cell type specific since in
hepatocytes (HepG2 cells) Akt3 had exclusively nuclear localiza-
tion, while significant amount of Akt1 was observed in the
cytoplasm (Figure S6B). Thus a moderate decrease in total Akt
expression and activity in Akt3/ macrophages can be associ-
ated with major lack of Akt activity and major effect on Akt
targets in the cytoplasm of these cells.
Akt3 Regulates ACAT-1 Expression by Promoting Its
Degradation via the Ubiquitin-Proteasome Pathway
To determine whether the increase in ACAT-1 expression was
a consequence of an increase in ACAT-1 transcript, we
assessed ACAT-1 mRNA level in WT, and Akt3/ MPMs by
RT-PCR and real-time RT-PCR. We observed no significant
difference between these two groups (Figure 7D). Furthermore,
no increase in the synthesis of ACAT-1 protein was found in
Akt3/ MPMs (Figure 7E). The elevation in ACAT-1 could be
due to an increase in protein stability. We assessed the half-life
of ACAT-1 protein inWT andAkt3/MPMs using cycloheximide
to inhibit protein synthesis. As shown in Figure 7F, the half-life
of ACAT-1 in WT MPMs was 8 hr, while in Akt3/ MPMs the
half-life of ACAT-1 increased to 18 hr. We next tested whether
two primary intracellular protein degradation pathways, the
ubiquitin-proteasome and lysosome pathways, are involved in
accelerated degradation of ACAT-1 in WT macrophages. Treat-
ment of WT MPMs, but not of Akt3/ with specific proteasome
inhibitor, MG132, resulted in a pronounced increase in ACAT-1
protein expression (Figure 7G). Chloroquine had no significant
effect on ACAT-1 expression. The majority of cellular proteinsell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc. 867
Figure 7. The Mechanism of Specific Regulation of ACAT-1 by Akt3
(A) Subcellular localization of Akt1 and Akt3 detected by the confocal immunofluorescence microscopy differs in MPMs. DAPI staining (blue, white arrow) is the
nuclear marker.
(B) Immunofluorescence showed no significant changes in Akt1 localization in Akt3/ MPMs.
(C) Immunofluorescence analysis of Akt1 (red) and Akt3 (green) localization in human differentiated THP-1 macrophages. Scale bar, 25 mm.
(D) Analysis of ACAT-1 mRNA expression in WT and Akt3/MPMs using semiquantitative RT-PCR (left panel) and quantitative real-time RT-PCR (right panel),
actin mRNA used as a loading control. n = 4.
(E) Immunoprecipitation of ACAT-1 from WT and Akt3/ macrophages lysates after a 2 hr pulse label with [35S]methionine. Equal amounts (500 mg) of protein
from macrophage cell lysates were immunoprecipitated with ACAT-1 antibodies and separated by SDS-PAGE before autoradiography. n = 3.
(F) MPMs fromWT andAkt3/mice were incubated with cycloheximide (10 mg/ml), and at the indicated time points, cells were harvested, lysed, and analyzed for
ACAT-1 levels by western blotting. GAPDH levels were used as a loading control. n = 3.
(G) Wild-type and Akt3/MPMs were treated with proteasome inhibitor MG132 (MG, 20 mM) or lysosome inhibitor chloroquine (chlo, 30 mM) for 16 hr. ACAT-1
and corresponding b-actin (control) protein level were examined by western blot analysis. n = 3.
(H) Cultured WT and Akt3/ MPMs were treated with MG132 (MG, 20 mM) for 16 hr and the cell lysates immunoprecipitated (IP) using anti-ACAT-1 antibody,
followed by SDS-PAGE and immunoblotting using anti-ubiquitin antibody and anti-ACAT-1 antibody.
(I) WT and Akt3/ MPMs were treated with 40 mM Akt inhibitor XI (AktiXI), 20 nM rapamycin (RAP), or 10 mM SB 415286 (SB4) for 18 hr. The expression of
ACAT-1 and b-actin (control) was assessed by western blot analysis. Lower panel shows densitometric quantification. n = 3.
(J) ACAT-1 recognition by phospho-Akt substrate antibody. Total cell lysates of WT and Akt3/ MPMs were prepared and immunoprecipitated using anti-
ACAT-1 antibody. IP product was analyzed using ACAT-1 and phospho-Akt substrate antibody. n = 6. Data represent means ±SEM. *p < 0.05 and **p < 0.01
versus wild-type; #p < 0.05 and ##p < 0.01 versus control.
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WT and Akt3/ MPMs were treated with MG132 and lysed,
and then ACAT-1 was immunoprecipitated and subjected to
SDS-PAGE and western blotting analysis using anti-ubiquitin
antibody. Inhibition of proteasome pathway in WT macrophages
resulted in significant accumulation of high-molecular-mass
polyubiquitinated protein smear (Figure 7H), suggesting that868 Cell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc.ACAT-1 is polyubiquitinated in macrophages and that the poly-
ubiquitinated forms of ACAT-1 are rapidly removed through the
proteasome pathway. Polyubiquitination of ACAT-1 isolated
from Akt3/ MPMs was significantly reduced as compared to
WT MPM (Figure 7H). Taken together, these results suggest
that Akt3 suppresses ACAT-1 expression by promoting
ACAT-1 degradation via the ubiquitin-proteasome mechanism.
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phosphorylates multiple intracellular targets. While the pharma-
cological inhibition of Akt in WT MPMs led to a significant
increase in ACAT-1 expression, no effect of inhibition of such
major signaling pathways downstream of Akt as glycogen syn-
thase kinase-3b pathway, mTOR pathway, or NF-kB pathway
was observed (Figure 7I and Figure S6C). Interestingly, ACAT-
1 possesses consensus phosphorylation sites for Akt, and
direct phosphorylation by Akt is known to promote degradation
via a proteasome pathway. To investigate whether ACAT-1
phosphorylation correlates with Akt3 expression, we immuno-
precipitated ACAT-1 from MPMs and performed a western blot-
ting analysis using a phospho-(Ser/Thr)-Akt substrate antibody
(Sano et al., 2007). ACAT-1 isolated from Akt3/ MPMs
exhibited significantly reduced staining by this antibody as
compared to WT MPMs (Figure 7J). We have also observed
that Akt3 and ACAT-1 can be coimmunoprecipitated from cell
lysate, suggesting a direct interaction (Figure S6D). These results
suggest an intriguing possibility that ACAT-1 is a direct target
of Akt3.
DISCUSSION
The specific role of Akt3 isoform in vivo is poorly understood.
To date, it has been shown that Akt3 plays a specific role in
brain development and function, as well as in selected types of
cancer (Davies et al., 2008; Easton et al., 2005; Nakatani et al.,
1999; Stahl et al., 2004; Tokuda et al., 2011; Tschopp et al.,
2005). In this study, we demonstrated that genetic ablation of
Akt3 leads to accelerated atherosclerosis in hyperlipidemic
ApoE/ mice. Bone marrow transplantation experiments
demonstrated that the atheroprotective role of Akt3 depends
on its expression in bone marrow-derived cells, presumably
macrophages. In vitro experiments have shown that even though
Akt3 in macrophages is a minor isoform, its deletion leads to
excessive intracellular accumulation of CE and increased foam
cell formation. Mechanistically, increased CE accumulation
and foam cell formation in the absence of Akt3 were linked to
an increase in lipoprotein uptake and an increase in ACAT-1
activity and protein level.
Macrophage foam cell formation is an early key step in athero-
sclerosis. Macrophage survival in an atherosclerotic lesion is
known to play an atheroprotective role in advanced atheroscle-
rotic lesions but a proatherosclerotic role in early lesions (Tabas,
2010). Akt is known to promote cell survival, and recent studies
have shown that Akt1, a major Akt isoform in macrophages,
regulates apoptosis and necrosis of these cells both in vitro
and in vivo (Fernandez-Hernando et al., 2007). Our results, on
the other hand, strongly suggest that macrophage Akt3 plays
aminor role inmacrophage survival, and that the proatheroscler-
otic phenotype of Akt3/ macrophages is apoptosis indepen-
dent. This finding is consistent with the previously reported
lack of the effect of Akt3 deficiency on cell survival in other cell
types (Wright et al., 2008).
Mechanisms of foam cell formation may include increased
uptake of atherogenic lipoproteins, disturbed intracellular pro-
cessing, and ineffective elimination of cholesterol from cells via
the cholesterol efflux pathway. We have ruled out changes in
cholesterol synthesis and cholesterol ester hydrolysis, andCa primary defect in cholesterol efflux machinery as significant
contributors to excessive CE accumulation in Akt3/ MPMs.
According to our data, at least two mechanisms contribute to
this effect. We observed a small but consistent increase in
modified lipoprotein uptake in Akt3/ MPMs, even though the
expression of three major scavenger receptors was not
changed. Mechanistically, this increase is explained by the
mild increase in pinocytosis that we found in Akt3/ MPMs. It
has been demonstrated that fluid-phase pinocytosis contributes
to macrophage cholesterol accumulation within mouse athero-
sclerotic plaques (Kruth, 2011). Theoretically, a mild increase in
lipoprotein uptake could lead to a significant increase in CE
accumulation in macrophages over time, but only if unmatched
by an equivalent increase in efflux. Our second observation
can provide a mechanism for the reduction in cholesterol efflux
in Akt3/ MPMs. We observed that macrophage Akt3 defi-
ciency specifically augments expression of ACAT-1, an enzyme
diverting cholesterol from the cholesterol efflux pathway by
esterifying cholesterol and promoting its storage in cytoplasmic
droplets. ACAT-1 is the major isoenzyme in lipid-laden macro-
phages, both in vitro and in vivo. It is localized in endoplasmic
reticulum (ER)-regulating cholesterol content in ER and plays
a critical role in CE accumulation in cells in atherosclerotic
lesions (Miyazaki et al., 1998).
The concept that increased accumulation of CE in macro-
phages is proatherogenic is supported by the demonstration
of increased atherosclerosis in mice with knockout of the two
major enzymes responsible for CE hydrolysis in macrophages
(Sekiya et al., 2009), as well as by the finding that overexpression
of cholesteryl-ester hydrolase in macrophages protects against
diet-induced atherosclerosis (Zhao et al., 2007). Overexpression
of ACAT-1 suffices to induce cholesterol ester accumulation
in vitro (Liang et al., 2004). We confirmed this observation using
RAW264.7 mouse macrophage cells. Complete suppression of
CE formation in macrophages in vivo as in ACAT-1 deficiency
leads to the formation of large macrophage-poor atherosclerotic
lesions, because someACAT-1 activity is required for themacro-
phage to survive in conditions of increased lipoprotein uptake,
typical for proatherosclerotic environment (Chang et al., 2009).
On the other hand, the concept that increased ACAT-1 expres-
sion inmacrophages plays a proatherosclerotic role is supported
by animal and in vitro studies (Ikenoya et al., 2007; Worthley
et al., 2007). Our in vivo and in vitro data suggest that genetic
manipulation leading to increased expression and activity of
ACAT-1 in macrophages is proatherogenic. Thus, published
data and our data suggest that both complete prevention of
cholesterol esterification and augmented accumulation of CEs
in macrophages promote atherosclerosis, but via different
mechanisms.
ACAT-1 is regulated at both transcriptional and posttransla-
tional levels. It is allosterically activated by the binding of choles-
terol (Chang et al., 2009). Expression of ACAT-1 in macrophages
is regulated by several cytokines, adipokines, hormones, and
bioactive peptides. While Akt involvement in the regulation of
cholesterol esterification has not been known, recent studies
have shown that the PI3K/Akt/mTORC1 pathway positively
regulates multiple genes involved in de novo synthesis of
cholesterol and other lipids via transcription factors SREBPs
(Duvel et al., 2010; Porstmann et al., 2009). This regulation isell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc. 869
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for which the synthesis of components for a new membrane,
such as cholesterol, is required. Interestingly, while ACAT-1
expression in ER contributes to cholesterol homeostasis, the
ACAT-1 gene is not under the control of the SREBP pathway
(Goldstein et al., 2006). Our studies suggest that Akt directly
and negatively regulates ACAT-1 expression. This parallel stim-
ulation of cholesterol synthesis and suppression of cholesterol
esterification in ER may be important for processes requiring
the generation of new cell membranes, such as cell growth or
phagocytosis.
We have shown that ACAT-1 is polyubiquitinated and
degraded in macrophages via the ubiquitin-proteasome system
in an Akt3-dependent manner. The mechanism triggering the
ubiquitin-proteasome pathway of ACAT-1 degradation needs
further investigation. Polyubiquitynation is often induced by
protein phosphorylation. Akt directly phosphorylates a number
of proteins participating in lipogenesis (Yellaturu et al., 2009).
Thus, one possibility is the direct phosphorylation of ACAT-1
by Akt3. This possibility is supported by the following ob-
servations: we ruled out three major pathways downstream
of Akt (mTOR, GSK-3, and NF-kB) as regulating ACAT-1
expression; there are two potential Akt phosphorylation sites
in ACAT-1 (Thr317 and Thr545), and we observed reduced
phosphorylation of ACAT-1 using phosphorylated Akt target
motif antibody in Akt3/ macrophages as well as evidence
for direct interaction of ACAT-1 and Akt3 in cells. Nevertheless,
whether ACAT-1 is directly phosphorylated, or whether another
pathway downstream of Akt3 is involved, has yet to be
established.
Specific contributions of three Akt isoforms to lipid regula-
tion are not known. We found that CE accumulations were
specifically increased in Akt3/ MPMs. One mechanism
providing specificity of Akt function is via regulation of intracel-
lular localization. While intracellular localization of Akt1 and
Akt3 could be nuclear, cytoplasmic, or both, depending on
the cell type (Santi and Lee, 2010), we observed that in murine
and human macrophages, localization of the two isoforms is
almost mutually exclusive. Akt1 has nuclear localization with
very little staining of the cytoplasm, while Akt3 staining was
mostly restricted to the cytoplasm. Localization within the
same cellular compartment could facilitate the postranslational
regulation of ACAT-1 by Akt3. In agreement with studies by
others, we found that ablation of one Akt isoform does not alter
the subcellular localization of another Akt isoform (Santi and
Lee, 2010). These findings may explain why Akt1 and Akt3
deficiencies have a different effect on lipid accumulation in
macrophages, and why Akt3 function is not compensated by
Akt1 in these cells. A molecular mechanism behind differential
localization of Akt isoforms is still missing. Nevertheless, our
finding adds additional evidence that Akt isoforms may have
nonredundant functions, even when they are expressed in the
same cell.
In conclusion, our study demonstrates that Akt3 plays an
antiatherogenic role in vivo, and identifies a previously unknown
isoform specific mechanism for this role. Furthermore, the
finding of selective regulation of ACAT-1 by Akt3 adds new
possibilities for pharmacological regulation of ACAT-1, which
may be of interest beyond the field of atherosclerosis.870 Cell Metabolism 15, 861–872, June 6, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animal Procedures
We used littermate-derived, sex-, age-, and genetic background-matched
mice in our experiments. Akt3/ and Akt1/ mice were generated as previ-
ously described (Chen et al., 2005, 2009). Akt3/mice were originally created
from 129Svj embryonic stem cells (ESCs) and backcrossedR63 to C57Bl/6.
After the last backcross, heterozygotes were mated to create background-
matched WT and Akt3/ mice for the present studies. ApoE/Akt3/
mice were created from a cross between 63 backcrossed Akt3/ and
ApoE/ (>203 backcrossed to C57Bl/6) mice to yield double heterozygotes
(R73 backcrossed). These were mated back to the ApoE/ and screened
for ApoE/Akt3+/ mice of both genders (R83 backcrossed). These were
then mated to yield background-matched ApoE/ and ApoE/Akt3/
siblings for the current experiments. Sex- and age-matched 8- to 12-week-
old littermates were used for the study. Atherosclerosis was induced by
feeding of 8-week-old ApoE/Akt3/ and ApoE/Akt3+/+ littermates (eight
males and four females in each group) with a Western diet containing 0.2%
cholesterol and providing 42% calories as fat (TD88137, Harlan Teklad) for
9 weeks. We performed all procedures according to protocols approved by
the Cleveland Clinic IACUC.
Bone Marrow Transplantation
Eight-week-old male or female recipient mice were lethally irradiated with
a single dose of whole-body irradiation (900 rads) on the day of transplantation.
Bonemarrow cells from the donor 7-week-oldmale or female ApoE/Akt3/
and ApoE/Akt3+/+ mice were isolated and injected into each recipient
mouse intravenously. Four weeks later, the mice were fed with a Western
diet for 10 weeks and then used for atherosclerotic lesion analysis. Bone
marrow and tail tissue of each animal were used to confirm bone marrow
reconstitution by PCR analysis.
ACAT-1 and ACAT-2 Immunoprecipitation and Western Blot
Analysis
MPMs were cultured with or without 50 mg/ml acLDL for 18 hr. Cells were
harvested and lysed. Each sample (100 mg) was incubated overnight at 4C
with rabbit anti-ACAT-1 antibody, rabbit anti-ACAT-2 antibody, or nonimmune
rabbit IgG. Then potein A or protein G Sepharose beads were added, and
incubation was continued for 4 hr at 4C. Beads were washed three times
with cell lysis buffer, boiled in Laemmli buffer, separated by SDS PAGE, and
analyzed by western blotting using mouse anti-ACAT-1, goat anti-ACAT-2,
or phospho-Akt substrate antibodies.
In Vitro Akt Kinase Activity Assay
In vitro Akt kinase activity was analyzed using Akt Kinase Assay Kit (Cell
Signaling) according to the manufacturer’s protocol. Briefly, MPMs were
cultured in 10%FBS/RPMI for 24 hr. Cells were harvested, washed once
with ice-cold PBS, and lysed with ice-cold nondenaturing lysis buffer. Immo-
bilized phospho-Akt beads were added to cell lysate for immunoprecipitation.
The pellet was incubated with 20 mg/ml GSK-3 fusion protein substrate and
0.2 mM ATP in kinase buffer for 30 min at 30C. Reaction was terminated
with 2 3 SDS sample buffer. Phosphorylation of GSK-3 was detected by
western blotting using phospho-GSK-3 (Ser21/9) antibody.
In Vitro ACAT Activity Assay
Protein samples of Akt3/ or WT MPMs were incubated with cholesterol,
Tyloxapol, BSA, and [14C]-Oleoyl CoA for 15 min at 37C. Then lipids were
extracted, separated, and 14C radioactivity determined by scintillation spec-
trometry. Full details are given in the Supplemental Information.
Atherosclerotic Lesion Analysis
Mice fed a Western-type diet for 9 or 10 weeks were euthanized by anesthetic
overdose. Hearts were perfused with PBS and 4% paraformaldehyde. For
en face analysis, the entire aorta from the heart, extending 5–10 mm after
bifurcation of the iliac arteries and including the subclavian right and left
common carotid arteries, was removed, dissected, stained with oil red O, and
evaluated for lesion development by morphometry of scanned images using
Adobe Photoshop and NIH Scion Image software (Febbraio et al., 2000).
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from the region of the proximal aorta through the aortic sinusesand stainedwith
oil red O, hematoxylin, and light green (Baglione and Smith, 2006). Morphom-
etry of lesions was made using ImagePro software (Media Cybernetics).
siRNA Transfection
Reagents used for siRNA transfection were purchased from Santa Cruz
Biotechnology. WT MPMs were treated with control siRNA, Akt1 siRNA, or
Akt3 siRNA according to the manufacturer’s protocol. The transfection
efficiency was assessed using FITC-conjugate control siRNA.
ACAT-1 Protein Stability
MPMs were cultured in RPMI/10% FBS medium in the presence of 10 mg/ml
cycloheximide for 0–24 hr and then harvested, and the expression of
ACAT-1 and GAPDH was determined by western blotting of total cell lysates.
Statistical Analysis
Data are presented as mean ±SEM. The statistical significance of differences
was evaluated using the Student’s t test or Mann-Whitney U test. Significance
was accepted at the level of p < 0.05. When multiple comparisons were made,
a Bonferroni correction was made for each test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.cmet.2012.04.020.
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